10-Q: Medifast Q2 Revenue Plunges 37% Amid Coach Decline

Medifast, Inc. reported a significant 37.4% revenue decrease in Q2 2025, driven by a sharp decline in active OPTA VIA coaches, despite returning to net income.

Summary

• Revenue for the three months ended June 30, 2025, decreased by $63.0 million, or 37.4%, to $105.6 million compared to $168.6 million in the prior year.
• Net income for Q2 2025 was $2.5 million, or $0.22 per diluted share, a significant improvement from a net loss of $8.2 million, or $0.75 per diluted share, in Q2 2024.
• For the six months ended June 30, 2025, revenue decreased by $122.0 million, or 35.5%, to $221.3 million compared to $343.3 million in the prior year.
• Net income for the six months ended June 30, 2025, was $1.7 million, or $0.15 per diluted share, up from $0.2 million, or $0.01 per diluted share, in the same period of 2024.
• The number of active earning OPTA VIA coaches decreased by 32.7% to 22,800 as of June 30, 2025, from 33,900 as of June 30, 2024.
• Average revenue per active earning OPTA VIA coach declined by 6.9% to $4,630 for Q2 2025 from $4,972 for Q2 2024.
• Selling, general, and administrative (SG&A) expenses decreased by $53.6 million, or 40.8%, in Q2 2025, primarily due to a $24.3 million reduction in coach compensation and non-recurring costs from Q2 2024.
• Other income increased significantly due to a $2.6 million gain on the sale of the investment in LifeMD common stock in Q2 2025, compared to a $4.2 million loss in Q2 2024.
• The company is undergoing a business transformation to adapt to the impact of GLP-1 weight loss medications, introducing tailored programs for different client needs.
• New initiatives like the EDGE program and Premier+ autoship program have been rolled out to support coaches and improve client acquisition and retention.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in core business metrics like revenue and active coaches. While net income improved, it was largely due to cost-cutting and a one-time gain, not a reversal of the underlying business trend. The company is in a challenging transformation period with uncertain outcomes.

Positives

• Achieved net income of $2.5 million in Q2 2025, a substantial improvement from a net loss of $8.2 million in Q2 2024.
• Operating loss significantly narrowed to $1.1 million in Q2 2025 from $7.9 million in Q2 2024, reflecting effective cost management.
• SG&A expenses decreased by 40.8% in Q2 2025, driven by lower coach compensation and the absence of significant non-recurring costs from the prior year.
• Realized a $2.6 million gain from the sale of LifeMD common stock in Q2 2025, contributing to other income.
• Cash and cash equivalents increased to $101.7 million at June 30, 2025, from $90.9 million at December 31, 2024.
• Maintained a strong capital position with stockholders' equity of $216.0 million and working capital of $160.3 million.
• Terminated the $225.0 million senior secured revolving credit facility with no outstanding borrowings, indicating financial independence.
• Launched new strategic programs like EDGE and Premier+ to enhance coach support, business building, and client retention in a changing market.

Negatives

• Revenue declined sharply by 37.4% in Q2 2025 and 35.5% for the six months ended June 30, 2025, primarily due to decreased sales volumes.
• The number of active earning OPTA VIA coaches fell by 32.7% year-over-year, indicating significant challenges in coach recruitment and retention.
• Average revenue per active earning OPTA VIA coach decreased by 6.9% in Q2 2025, reflecting lower productivity per coach.
• Gross profit decreased by 37.9% in Q2 2025 and 35.8% for the six months ended June 30, 2025, in line with the revenue decline.
• Net cash flow provided by operating activities decreased significantly to $28 thousand for the six months ended June 30, 2025, from $20.4 million in the prior year period.
• Operating loss for the six months ended June 30, 2025, worsened to $2.3 million from a slight income of $64 thousand in the prior year, primarily due to lower gross profit.
• Experienced a loss of leverage on fixed costs due to lower sales volumes, partially offsetting SG&A reductions when viewed as a percentage of revenue for the six-month period.

Risks

• The rapid acceptance and surging popularity of GLP-1 weight loss medications pose a significant competitive threat and have fundamentally impacted the weight loss market.
• Continued challenges with client acquisition are driving the decrease in active earning OPTA VIA coaches and overall revenue decline.
• Macroeconomic uncertainties, including inflation, tariffs, and changes in commodity prices, could impact the company's cost structure and consumer spending.
• Prolonged tariff uncertainty may influence consumer sentiment and purchasing behavior, potentially reducing demand for products.
• The weight loss industry is highly competitive, with a multitude of products and programs, including pharmaceutical products, surgical interventions, and digital tools.
• The company is subject to various litigation and similar proceedings that could materially adversely affect its results of operations, financial position, or liquidity if unfavorably resolved.

Future Outlook

The company is executing a comprehensive business transformation to succeed in an environment impacted by GLP-1 weight loss medications, developing distinct coach-supported program offerings tailored to clients who have never used medications, those currently using them, and those managing weight after stopping them. The company intends to continue actively monitoring macroeconomic developments and updating practices accordingly.

Management Comments

• We are a well-capitalized business with strong and effective leadership that has grown its lifestyle brand, OPTA VIA, into a significant health and wellness brand.
• We believe that our integrated approach that combines lifestyle coaching, community support, and where warranted, access to medical solutions through LifeMD, positions the business to meet the needs of a broader spectrum of clients.
• Medifast is ensuring our OPTA VIA coaches are best positioned for success in the GLP-1 environment.
• Our scientifically designed Fuelings, as well as innovative products like OPTA VIA ASCEND and OPTA VIA ACTIVE, continue to address the needs of clients who do not wish to use medications.
• We believe our coach-based model is scalable and drives both client success and growth, and is a key competitive advantage.
• Medifast has perfected our model over the last 40+ years, with habits, coaches, and community at the core, and we will continue to innovate as the industry evolves.

Industry Context

The weight loss industry is highly competitive and has been fundamentally impacted by the rapid acceptance and surging popularity of GLP-1 weight loss medications. These medications have brought more attention to weight loss but do not provide a 'magic solution' for sustainable lifestyle change, as two-thirds of weight lost on GLP-1s is typically regained within 12 months of stopping treatment. Medifast is adapting by integrating GLP-1 support through its LifeMD collaboration and focusing on its coach-supported, habit-based approach for clients across different stages of their wellness journey, including those coming off GLP-1s.

Comparison to Industry Standards

• The company believes it has a competitive advantage over traditional diet companies by offering a holistic wellness solution, personalized empathetic support from coaches, promoting lifelong habit development through the Habits of Health Transformational System, and fostering a vibrant health and wellness community.
• The OPTA VIA model is differentiated from traditional direct selling companies by its client-centric approach with one sales price for coaches and clients (no tiered pricing), a focus on holistic health rather than solely product sales, a direct-to-consumer shipping model, and a unified training system for coaches.
• A clinical study cited by the company indicated that clients on the OPTA VIA 5 & 1 Plan lost 10 times more weight and 17 times more fat than a self-directed control group, highlighting the efficacy of their specific program compared to unguided weight loss efforts.

Corporate Governance

Legal Proceedings

• The company is subject to a variety of litigation and similar proceedings arising from the ordinary course of business. Management does not believe these will have a material adverse effect on results of operations, financial position, or liquidity, but acknowledges that outcomes cannot be predicted with certainty and could be materially adverse.

Related Party Transactions

• The company sold all its holdings in LifeMD, Inc. common stock during Q2 2025, realizing a gain of $2.6 million for the quarter and $3.2 million for the six months ended June 30, 2025.
• The collaboration agreement with LifeMD, Inc. for providing services to stand-up the collaboration continues, despite the sale of equity holdings. No expenses were recognized for services performed by LifeMD for the six months ended June 30, 2025, compared to $3.3 million in the prior year period.

Stakeholder Impact

• Shareholders: Experienced a significant decline in revenue and active coaches, but net income improved due to cost management and a one-time investment gain. The stock repurchase plan remains active.
• OPTA VIA Coaches: The number of active earning coaches decreased substantially, impacting their compensation. New programs (EDGE, Premier+) are designed to support their business growth and retention.
• Clients: New tailored programs and continued access to GLP-1 clinicians through the LifeMD collaboration aim to better serve diverse client needs in the evolving weight loss market.
• Employees: SG&A reductions, including lower coach compensation, may indicate broader operational adjustments that could indirectly affect employees, though no direct impact was specified.

Next Steps

• Continue executing the comprehensive business transformation to adapt to the GLP-1 environment.
• Further build out program offerings tailored to three specific client categories (non-medication users, GLP-1 users, post-GLP-1 users).
• Enhance digital tools and improve the client experience.
• Monitor the impact of new coach programs like EDGE and Premier+ on client acquisition and retention.
• Actively monitor macroeconomic developments and adjust business operations as needed.
• Evaluate the impact of adopting new accounting pronouncements (ASU 2023-09 and ASU 2024-03) on consolidated financial statements.

Key Dates

Recommendation

The company faces severe headwinds with a substantial decline in revenue and active coaches, indicating a shrinking core business. While net income improved, this was largely due to aggressive cost-cutting and a one-time gain from an investment sale, not a fundamental turnaround in sales. The strategic transformation is necessary but its success is uncertain given the competitive landscape and the disruptive impact of GLP-1 medications. The significant drop in operating cash flow further highlights underlying business weakness. Investors should consider selling due to the ongoing deterioration of key operational metrics and the high uncertainty surrounding the business transformation.

Keywords

Weight Loss, Health and Wellness, Direct Selling, OPTA VIA, GLP-1, Nutrition, Diet, Coaching, SEC Filing, Quarterly Report